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Abstract
Background: Molecular descriptors are essential for many applications in computational chemistry, such as ligand-based
similarity searching. Spherical harmonics have previously been suggested as comprehensive descriptors of molecular
structure and properties. We investigate a spherical harmonics descriptor for shape-based virtual screening.
Methodology/Principal Findings: We introduce and validate a partially rotation-invariant three-dimensional molecular
shape descriptor based on the norm of spherical harmonics expansion coefficients. Using this molecular representation, we
parameterize molecular surfaces, i.e., isosurfaces of spatial molecular property distributions. We validate the shape
descriptor in a comprehensive retrospective virtual screening experiment. In a prospective study, we virtually screen a large
compound library for cyclooxygenase inhibitors, using a self-organizing map as a pre-filter and the shape descriptor for
candidate prioritization.
Conclusions/Significance: 12 compounds were tested in vitro for direct enzyme inhibition and in a whole blood assay.
Active compounds containing a triazole scaffold were identified as direct cyclooxygenase-1 inhibitors. This outcome
corroborates the usefulness of spherical harmonics for representation of molecular shape in virtual screening of large
compound collections. The combination of pharmacophore and shape-based filtering of screening candidates proved to be
a straightforward approach to finding novel bioactive chemotypes with minimal experimental effort.
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Introduction
Ligand-based virtual screening [1,2], quantitative structure-
property and structure-activity relationships [3,4], and other
concepts in computational medicinal chemistry are based on the
similarity principle [5], which states that (structurally) similar
compounds generally exhibit similar properties. Such methods
require quantitative representations of molecules, usually in the
form of chemical descriptors, i. e., computable numerical
attributes in vector form [6].
Numerous molecular 3D-descriptors and alignment methods
have been proposed. Examples include CoMFA (comparative
molecular field analysis) [7], Randic molecular profiles [8], 3D-
MoRSE code (3D-molecule representation of structures based on
electron diffraction) [9], invariant moments and radial scanning
and integration [10], radial distribution function descriptors [11],
WHIM (weighted holistic invariant molecular descriptors) [12],
length-to-breadth ratios [13], USR (ultrafast shape recognition,
based on statistical moments) [14], ROCS (rapid overlay of
chemical structures, based on Gaussian densities) [15], VolSurf
(volumes and surfaces of 3D molecular fields) [16], GETAWAY
(geometry, topology, and atom weights assembly) [17], and shrink-
wrap surfaces [18], to name just a few prominent representatives.
In computer graphics, several methods exist for the more
general problem of comparing arbitrary 3D objects [19,20],
including distribution-based shape histograms [21], the D2 shape
descriptor [22], and, the scaling index method [23]; the view-
based methods of extended Gaussian images [24], and the light
field descriptor [25]; the surface decomposition-based methods of
Zernike moments [26], REXT (radialized spherical extent
function) [27], and spherical harmonics descriptors [28].
Spherical harmonics have been used in cheminformatics as a
global feature-based parametrization method of molecular shape
[28–38]. Their attractive properties with regard to rotations make
them an intuitive and convenient choice as basis functions when
searching in a rotational space [31]. A review article by
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harmonics to protein structure comparison, ligand binding site
similarity, protein-protein docking, and virtual screening. Jakobi et
al. [37] use spherical harmonics in their ParaFrag approach to
derive 3D pharmacophores of molecular fragments. Recently,
Ritchie and co-workers have applied the ParaSurf and ParaFit
methodologies [32,33] (Cepos InSilico Ltd., Erlangen, Germany)
in a virtual screening study on the directory of useful decoys
(DUD) data set [39], which motivates 3D shape-property
combinations specifically for flexible ligands [40]. The DUD data
set was also used in a comparative analysis of the performance of
various shape descriptors alone and in combination with property
and pharmacophore features [41]. See the section on related
methods for further discussion of spherical harmonics approaches.
In this work, we introduce a partially rotation-invariant
descriptor of molecular shape based on spherical harmonics
decomposition coefficients. The idea is to decompose the
molecular surface using spherical harmonics and to use the norm
of the decomposition coefficients as a description of molecular
shape. In this, we take advantage of the fact that the norm of the
coefficients does not change under rotation around the z-axis,
which we align to the primary axis of the molecule. We
retrospectively evaluate our descriptor, and prospectively apply it
to screen for novel inhibitors of the enzymes cyclooxygenase-1
(COX-1) and cyclooxygenase-2 (COX-2). Particular focus is on
the practical application of the virtual screening technique as an
evaluation of its actual suitability for early-phase drug discovery.
Materials and Methods
Spherical harmonics
Let l[f0,1,2,...g, let jmjƒl, let (h,w) indicate spherical
coordinates, and let Pm
l denote the Legendre polynomials [42].
The spherical harmonics [43] Ym
l of order l (frequency, angular
quantum number) and degree m (azimuthal quantum number),
Ym
l (h,w)~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2lz1
4p
(l{m)!
(lzm)!
s
Pm
l (cosh)eimw, ð1Þ
form an orthonormal (with respect to integration over the unit
sphere) and complete set of basis functions (Fig. 1). They are
solutions to Laplace’s differential equation +2Y~0 in spherical
coordinates [44].
Any square-integrable spherical function f(h,w) can be
decomposed as
f(h,w)~
X ?
l~0
X l
m~{l
cm
l Ym
l (h,w), ð2Þ
with complex coefficients cm
l . The spherical harmonics decompo-
sition can be viewed as a generalization of the Fourier
decomposition to three dimensions [45].
The coefficients cm
l of an harmonic expansion can be found using
the orthonormality property. Multiplying each side of Eq. 2 by the
complex conjugate Y
m
l (h,w) and integrating over the sphere yields
cm
l ~
ð p
h~0
ð 2p
w~0
f(h,w)Y
m
l (h,w)sin(h)dwdh: ð3Þ
Small values of l correspond to low frequencies, and describe the
overall low-resolution shape; higher values of l add finer, high-
frequency detail. The coefficients are unique, and can therefore be
used as feature vectors for shape description.
Rotation of a molecule (its shape function f) changes the
coefficients. A conventional solution is to define a canonical
orientation of the molecule. For the purpose of shape comparisons,
this implies an alignment of the compared molecules, with all
associated problems and computational requirements. As an
alternative, we use a partial orientation in conjunction with
certain rotational invariance properties of the coefficients.
Descriptor definition
Let X~(~ x x1,...,~ x xn)
T[R
n|3 denote the Cartesian coordinates of
points ~ x x1,...,~ x xn[R
3 sampled from a molecular surface. We
assume that the surface is ‘‘star-like’’ (single-valued) in the sense
that rays radiating outward from the molecule’s origin intersect the
surface only once (this is more of an issue for proteins; as argued
elsewhere [35], small molecules are little, if at all, affected). Let
B[R
n|k denote the spherical harmonics basis functions Ym
l
evaluated at ~ x x1,...,~ x xn, 0ƒlƒL, {lƒmƒl, with L[N the
maximum order used and k~
PL
l~0
Pl
m~{l 1~(Lz1)
2 the
number of basis functions. The sampled molecular surface X can
be reconstructed using a matrix C[R
k|3 of coefficients as X~BC.
The coefficient matrix is given by C~B{X, where B{ denotes
the pseudo-inverse [46] of B.
Lemma. The p-norm of the rows of C does not change under
rotation around the z-axis (polar axis, change in w).
Proof It is sufficient to consider a single coefficient, i.e., n~k~1,
and ~ c c~b{1~ x x~(x,y,z)=b. Here, ~ x x~(x,y,z)[R
3 is a sampled
surface point, ~ c c[R
3 are coefficients, and b[R is the spherical
harmonics basis function Ym
l . From Eq. 1, it is clear that if w
changes, only the part exp(imw) of the spherical harmonic basis
function Ym
l (h,w) changes, while the rest of Ym
l stays constant.
Thus, b~exp(imw)d for some constant d[R depending only on
m,l,h, but not on w. Since jexp(imw)j~1, and thus jbj~jdj,
Figure 1. Spherical harmonics by order lƒ3 (columns, left to
right) and degree m[f{l,...,lg (rows, bottom to top). Shown are
negative real (blue), positive real (red), negative imaginary (green), and
positive imaginary (yellow) parts of Ym
l .
doi:10.1371/journal.pone.0021554.g001
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PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e21554Figure 2. Surface reconstruction using spherical harmonics. Shown are the original surface (top left), the surface after alignment to the z-axis
(top middle), and reconstructions using spherical harmonics of order l up to 1 (top right), 3 (bottom left), 6 (bottom middle), and 9 (bottom right).
doi:10.1371/journal.pone.0021554.g002
Figure 3. Spherical harmonics decomposition coefficients cm
l of a molecular surface for 0ƒlƒ9. The original (top left) and the rotated
(top right) surfaces yield coefficients with identical norm (bottom), up to numerical noise (differences were below 2:10{13).
doi:10.1371/journal.pone.0021554.g003
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After a rotation around the z-axis (a change in w), the same holds
for the rotated point ~ x x0~(x’,y’,z’) and its coefficient ~ c c0, i.e.,
jj~ c c0jjp~jdj
{1jj~ x x0jjp. Since the rotation matrix is unitary,
jj~ x xjjp~jj~ x x0jjp, and it follows that jj~ c cjjp~jj~ c c0jjp.
Our spherical harmonics descriptor is the k-component vector
(jj~ c c0
0jjp,jj~ c c{1
1 jjp,jj~ c c0
1jjp,jj~ c c1
1jjp,jj~ c c{2
2 jjp,...,jj~ c cL
Ljjp)
of the norms of the coefficients. It is a description of molecular
shape that is invariant to rotations around the z-axis.
Before spherical harmonics decomposition, we place molecules
into a common frame of reference by translating their center of
gravity to the coordinate system origin and by aligning their first
principle component (the direction of maximum variance as given
by principle component analysis [47]) with the z-axis. In other
words, we align molecules according to their longest spatial extent,
and then apply our descriptor which is invariant to rotations
around the z-axis.
Descriptor computation
Gaussian contact surfaces [48] of all compounds were computed
using MOE (Molecular Operating Environment, version 2009.10,
Chemical Computing Group Inc., Montreal, Canada, www.
chemcomp.com ). Spherical harmonics decomposition was then
carried out on the vertices of these surfaces, giving approximate
coefficients [49]. To limit computational expense, we truncated
spherical harmonics expansions after order L~9. The resulting
k~(9z1)
2~100 decomposition coefficients were sufficient to
represent fine molecular detail and approximately reconstruct the
original molecular surfaces (Fig. 2). The partial rotational
invariance of the coefficient norms jjcm
l jj is demonstrated in
Fig. 3. Computation was done in Matlab (The MathWorks,
version R2007a, www.mathworks.com ), partly based on code by
Dr. Andrew Hanna (University of East Anglia, United Kingdom,
www.cmp.uea.ac.uk/,aih ). Average computing time was v3
seconds per compound, which is acceptable for medium-sized
libraries but will require speed-up for high-throughput virtual
screening.
Related methods
Spherical harmonics have been widely used in cheminformatics
as a global feature-based parametrization method of molecular
shape [28–38]. Most current approaches, including ours, use the
center of gravity as the center of the spherical harmonics
decomposition. Molecular surface sampling can be done by
sampling iso-probability surfaces of molecular property densities.
One aspect in which methods differ is the way they deal with
rotations in 3D space.
Ritchie and Kemp [31] apply the rotational property of
spherical harmonics (a rotation of the surface can be simulated
by rotating the expansion coefficients) to maximize the pairwise
superposition of two molecules. The software ParaSurf superposes
molecules using a brute-force rotational search over the three
Euler rotation angles [50]. In a recent publication, Cai et al. [36]
use a similar approach to obtain the minimal root-mean-square
distance between a ligand molecule and a target protein. In these
related studies, molecular surfaces were rotated by transforming
their expansion coefficients.
Standard orientation of compounds prior to spherical harmon-
ics decomposition was proposed by Morris et al. [34]. Their work
registered molecules and binding pockets in a standard frame by
translating their center of mass to the coordinate origin and
aligning their variance-covariance matrix to the axes of the
coordinate system. They then use the coefficients of a real
spherical harmonics expansion to describe and compare the
molecular shape of binding pockets and ligands. This approach
aligns molecules to minimize rotation-dependent differences in the
coefficients.
Rotation-invariant spherical harmonics descriptors were applied
by Kazhdan et al. [28] and Mavridis et al. [35,51], using the fact
that expansion coefficients of the same order l transform among
themselves to construct rotationally invariant spherical harmonics
coefficients jj
Pl
m~{l cm
l jj2. In their approach, coefficients of the
same order l are binned together, thereby losing information
contained in the individual degrees m, but gaining complete
rotational invariance.
In this work, we combine partial orientation of the molecules
with the magnitude of the expansion coefficients as a partially
rotation-invariant shape descriptor. Our proposed descriptor
retains more information than the spherical harmonics descriptors
by Kazhdan et al. [28] and Mavridis et al. [35,51] in the sense that
coefficients within the same order are not summed up, but kept.
Compared with standard orientation methods, our descriptor is
potentially less susceptible to problems in the orientation step than
most others because only the first (and most stable) principle
component is used for orientation.
Retrospective evaluation
For retrospective validation, we ranked the compounds in a
database according to their similarity to a reference compound, as
measured by Euclidean distance and our descriptor. Two concep-
tually different collections of reference data wereused, the DUD data
set (release 2, from http://dud.docking.org/r2 , unmodified data)
[39], and the COBRA data set (version 10.3, 11 244 compounds
annotated with activity on a total of 677 individual macromolecular
targets) [52]. COBRA 10.3 contains 168 COX-2 inhibitors.
Gaussian contact surfaces were generated with the MOE
2009.10 (Molecular Operating Environment, Chemical Comput-
ing Group Inc., Montreal, Canada, www.chemcomp.com )
GaussianSurface function, with parameter pos set to ‘aPos a’,
rad ‘dock_aRadius a’, nearpos ‘aPos a’, neardist ‘5’, maxMb ‘1’,
and fuzzy ‘0’. All other parameters were kept at their default
values. Virtual screening experiments in COBRA were carried out
using a single conformation generated by CORINA (version 2007,
Molecular Networks GmbH, Erlangen, Germany, www.molecu-
lar-networks.com ).
We used the selective COX-2 inhibitor SC-558 and the non-
selective inhibitor indomethacin as queries for ligand-based
similarity searching, with the conformations extracted from the
crystal structure (protein data bank [53] identifiers (PDB ID) 6cox
[54] and 4cox [54]). Enrichment factors [55], receiver operating
characteristic curves (ROC curves [56]), and the area under these
curves (ROC AUC) were used as performance measures.
Prospective virtual screening
We screened the ChemBridge compound pool (457 226
compounds, ChemBridge Corp., San Diego, USA, www.chem-
bridge.com) for potential COX ligands using a single CORINA
conformer query as in the retrospective screening. The database
was preprocessed using the ‘‘washing’’ procedure in MOE
(protonation of strong bases and de-protonation of strong acids;
all other parameters were kept at their default values).
Spherical Harmonics Descriptor
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feature-based compound ranking, the screening compound pool
was pre-filtered using a self-organizing map (SOM [57]) trained on
the ChemBridge collection and 275 COX-1 and COX-2
inhibitors from the COBRA database. SOM topology was toroidal
with 20|20 neurons (1 200 molecules per neuron on average);
compounds were represented using the 150-dimensional CATS2D
topological pharmacophore descriptor [58,59] and compared
using the Manhattan distance. The initial width of the Gaussian
neighborhood function was set to 5; training was terminated after
5:106 steps (using each compound 10 times on average). We used
the MOLMAP software tool for SOM generation [60].
After pre-filtering, 21 950 compounds of the ChemBridge
database that were similar to the COX inhibitors from the
COBRA database were retained for virtual screening using our
spherical harmonics shape descriptor. Two potent COX inhibitors
served as reference molecules (queries; Fig. 4). All parameters were
set to the values used in retrospective virtual screening. The
spherical harmonics descriptor was calculated for the 21 950
retained molecules and for the two reference molecules.
Enzyme inhibition assay
Inhibition of COX-1 (ovine) and COX-2 (human recombinant)
activity was measured using a COX inhibitor screening assay kit
(Cayman Chemicals, Ann Arbor, MI, USA, www.caymanchem.
com ), according to the manufacturer’s protocol. SC-560, a
selective COX-1 inhibitor, and celecoxib, a selective COX-2
inhibitor, served as positive controls. The COX inhibitor
screening assay directly measures the amount of prostaglandins
PGE2, PGD2 and PGF2a produced by SnCl2 reduction of COX-
derived PGH2. In addition to this protocol, the amounts of
prostaglandins were quantified by LC-MS/MS analysis as
described previously [61].
Whole blood assay
COX-1 whole blood assay. One-milliliter heparinized
human blood samples were incubated with 4ml test substance (in
DMSO) or 4ml DMSO (control) for 10 min at 370C. After this,
thrombocyte aggregation was stimulated by addition of calcium
ionophore A23187 (50mM) for 30min at 370C. Plasma was
separated by centrifugation for 20min at 2000rpm, 40C and kept
at {800C until assayed for TXB2 by LC-MSMS (see below).
COX-2 whole blood assay. For the determination of COX-
2 activity, 1ml of heparinized human blood was incubated at
370C with 10ml of acetylsalicylic acid (1mgml
{1 in PBS), 4ml
DMSO or 4ml inhibitor (in DMSO) for 10min. After this, 2ml of
LPS (5mgml
{1 in DMSO) was added and incubated for 24hr at
370C. The reaction was terminated by quickly chilling on ice.
Plasma was separated by centrifuging (20min, 2000rpm, 40C),
stored at {800C until analysis of prostaglandins by LC-MS/MS
within two weeks.
Extraction procedure. 250ml plasma was incubated with
600ml4 5 m MH 3PO4, 100ml0 :15M EDTA, 10ml BHT
(butylated hydroxytoluene, 2mgml
{1), 20ml MeOH, 20ml
internal standard PGE2{d4 (25ngml
{1), PGD2{d4
(25ngml
{1), PGF 2a{d4 (10ngml
{1), 6k PGF{1 a{d4
(10ngml
{1), TXB2{d4 (25ngml
{1) for 1min, and passed
through a ABS ELUT-Nexus cartridge (Varian, Darmstadt,
Germany) preconditioned with methanol (1ml), followed by
distilled water (1ml). The cartridge was washed with distilled
water (1ml) and 30% MeOH (1ml). PGE2, PGF2a,
6{keto{PGF la and TXB2 were eluted with hexane-
ethylacetate-isopropranolol (30:65:5, v/v, 1ml). After vaporating
the solvent under nitrogen atmosphere, the residue was
reconstituted in 50ml acetonitrile / formic acid. PGE2
concentrations were quantified by means of a validated LC-MS/
MS assay described previously [61]. The lower limit of
quantification was 10pgml
{1.
Results and Discussion
We validated our spherical harmonics (SpH) descriptor in a
retrospective setting (statistical validation on known data), and in a
prospective study to obtain biochemical confirmation of our
model.
Retrospective evaluation
As a first analysis, we used the DUD compound collection for a
preliminary comparison of selected shape- and structure-based
virtual screening methods. ROC AUC [62] values were computed
Figure 4. Reference COX inhibitors used for prospective
screening with the shape descriptor. Indomethacin (top, PDB ID
4cox), a non-selective COX inhibitor, and, SC-558 (bottom, PDB ID 6cox),
a selective COX-2 inhibitor.
doi:10.1371/journal.pone.0021554.g004
Table 1. Results (ROC AUC) of retrospective virtual screening
of DUD data set for COX-2 inhibitors.
Single query DUD COX-2
Method SC558 Indomethacin average + std.dev.
CATS2D 0.76 0.49 0.636 0.14
LIQUID v.1 0.59 0.60 0.586 0.10
LIQUID v.2 0.80 0.61 0.746 0.12
PRPS 0.83 0.15 0.766 0.19
SpH 0.91 0.84 0.866 0.12
ShaEP 0.89 0.79 0.616 0.03
a
ROCS n.d. n.d. 0.68
a
aValues reproduced from the original study by Vainio et al. [68], with ShaEP and
ROCS run in ‘shape-only’ mode.
DUD COX-2 data: 426 actives, 13 289 decoys. Query SC558 has PDB ID 6cox;
indomethacin has PDB ID 4cox. n.d.=not determined.
doi:10.1371/journal.pone.0021554.t001
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interval ½0,1 , with values closer to 1 indicating higher enrichment
of actives in a ranked list of compounds. The analysis was limited
to the original COX-2 data from DUD (426 actives, 13 289
decoys). We did not perform exhaustive comparative analyses of
virtual screening performance or focus on ‘early recognition’ of
actives [63,64], as the primary purpose of this study was to
determine whether our SpH descriptor might be a useful shape-
based filtering criterion for COX inhibitors. Retrospective
screening was restricted to COX-2, our original target.
Table 1 summarizes the results obtained for CATS2D
(topological pharmacophore descriptor [58]), LIQUID (three-
dimensional pharmacophore descriptor using Gaussian feature
points; v1: hydrogen-bond donors, hydrogen-bond acceptors,
lipophilic [65]; v2: additional aromatic, positive and negative
charge features (manuscript in preparation)), PRPS (Gaussian
pseudoreceptor model [66,67]), ShaEP (field-based subgraph
matching [68]), and ROCS (Gaussian shape model [15,69]). For
the DUD COX-2 data, ROC AUC values indicate better than
random performance for all methods. SpH yielded an average of
0.86, which compares to Ritchie’s ParaFit spherical harmonics
descriptor (note that the ParaFit ROC AUC value is not given in
the original publication; we estimated it from graphical material
provided in the article’s supplementary material [41]). Among the
tested methods, SpH performed best for the selective COX-2
inhibitor SC-558 (Fig. 4) yielding a ROC AUC=0.91. Notably,
high values were also obtained for indomethacin (Fig. 4), a non-
selective COX inhibitor (COX-1 IC50 =18 nM; COX-2
IC50 =26 nM) [70]. Apparently, only the PRPS pseudoreceptor
model distinguished between the selective (ROC AUC=0.83) and
the non-selective (ROC AUC=0.15) query.
In contrast to DUD (unmodified data), the COBRA database
contains only druglike bioactive compounds. Ranking of the
COBRA database with SC-558 as query resulted in an enrichment
factor (computed for the first percentile) of 23. We compared this
result to those obtained by the shapelets [71] method from our
group, using the same version of the COBRA database and the
same reference structure. The shapelets shape-only virtual
screening method achieved a comparable enrichment factor of
24. ROC curves are presented in Fig. 5 (numbers for shapelets
refer to COBRA version 8.4 containing 8 311 compounds
including 136 COX-2 inhibitors).
Figure 6. Self-organizing map projection of the ChemBridge database in CATS topological pharmacophore space, using a 20|20
toroidal grid. Colors correspond to the number of compounds clustered, separately scaled for each plot, with z indicating empty neurons. The left
panel presents the distribution of the 457 226 compounds from the ChemBridge database, the right panel shows the 275 COX ligands from the
COBRA database.
doi:10.1371/journal.pone.0021554.g006
Figure 5. Receiver operating characteristic (ROC) curves for
virtual screening by ranking against the COX-2 ligand SC-558
(PDB ID 6cox). Shown are curves for shapelets (solid red line), and
spherical harmonics descriptor (dashed green line).
doi:10.1371/journal.pone.0021554.g005
Spherical Harmonics Descriptor
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21554In summary, our spherical harmonics coefficients-based
approach SpH achieves notable enrichment of actives and
seems suitable for COX-2 inhibitor retrieval. This outcome is
in agreement with the study of shape-based virtual screening
approaches by Ritchie et al. [41], who report high hit rates for
COX-2 using shape descriptors. We conclude that spherical
harmonics-based decomposition of molecular shape captures
structural features that are relevant for virtual screening. Due
to the limited number of published prospective applications
[72], it seems premature to render any conclusion regarding
certain implementation preferences or ‘best-in-class’ spherical
harmonics methods. To further assess our SpH approach, we
performed a prospective study using SpH in a virtual
screening cascade with the aim to identify new COX
inhibitors.
Prospective virtual screening
Virtual screening. We used a SOM to pre-select potential
COX inhibitors from the screening compound pool. The SOM
(Fig. 6) of COX activity islands contains six neurons with more
than three ligands (neurons (1,16), (1,14), (1,15), (7,18), (18,14),
(10,14) with 49, 25, 15, 14, 12, 11 ligands, respectively). We
selected all compounds from the ChemBridge database contained
in these neurons, 21 950 in total (5% of the pool).
In the second virtual screening step, SpH was used for shape-
based filtering. Two reference molecules (SC-558 and indometh-
acin; Fig. 4) resulted in two ranked lists of the pre-filtered
ChemBridge compounds. 10 duplicates were found among the 50
top-ranking compounds from the two lists (20% overlap). In total,
12 compounds were selected by visual inspection, preferring
potentially new scaffolds (‘cherry-picking’, Fig. 7), and submitted
Figure 7. Compounds selected for the COX inhibition assay.
doi:10.1371/journal.pone.0021554.g007
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whole blood assay.
Assay results
We determined the COX-inhibitory activity of 12 compounds
by performing a commercially available competitive COX-
inhibition assay using purified COX-1 (ovine) and COX-2 (human
recombinant) enzymes. Compounds 5 and 9 inhibit COX-1 in a
concentration dependent manner (Fig. 8 and Table 2). At 100mM
compounds 5 and 9 inhibit COX-1 activity to 72% and 89%,
respectively. Both compounds have only marginal effects on
COX-2-activity at concentrations up to 100mM. All other
substances have no effect on COX-1 or COX-2 activity in this
in vitro assay. While this outcome supports our general virtual
screening approach, we failed to retrieve COX-2 inhibitors. This
might be a consequence of using the selective COX-2 inhibitor
SC-558 in combination with the non-selective COX inhibitor
indomethacin as queries for the spherical harmonics shape filter.
Apparently, the COX activity island on the SOM and SpH
consensus filtering eliminated COX-2 specific features. It is also
possible that there were no hitherto unidentified COX-2 ligands in
the compound pool.
In the whole blood assay (Fig. 9, Table 3), compounds 5 and 9
are less effective, with maximum COX-1 inhibition of about 30%
and no COX-2 inhibitory efficacy. Interestingly, in this assay,
compounds 6, 10, 2 and 8 inhibit TXB2 production in a
concentration dependent manner up to 72%, 72% and 61% at
100mM, respectively. Compounds 6 and 10 have only marginal
inhibitory potency on PGE2 production, which points to selective
COX-1 inhibitors in vivo. Compound 2 also inhibits PGE2
production comparable to TXB2, indicating that this compound
is a COX-unselective inhibitor. In contrast, substance 8 increases
the PGE2 amount in a concentration dependent manner, which
argues for an activator of PGE2 production in the cellular context.
All other compounds show only very weak or no effect on PGE2
production.
The inhibitory data obtained from the whole blood assay might be
meaningful for further hit optimization. Compounds that are active
in this assay are not snatched away by binding to serum albumin, but
cross the cell membrane and overcome possible interactions with
cellular substances or enzymes.This could explain why compounds 5
and 9 a r ea c t i v ei nt h ee n z y m ea s s a y ,b u ti n a c t i v ei nt h ew h o l eb l o o d
assay.Incontrast,compounds6,10,2and 8,whichweremoreactive
in the whole blood assay, possibly interact with the arachidonic acid
pathway in other ways than direct inhibition of COX-1 or COX-2.
Also, these compounds might be metabolized by cellular enzymes to
more active derivatives, but this hypothesis needs to be tested by
further experiments. Compound 8 is of special interest, as it induces
PGE2 production up to 322%. This increase could be due to an
activation of enzyme activity, possibly by binding to the ‘‘inactive’’
monomer of the COX-homodimer complex [73,74], or, due to an
enhancement of COX-2 protein, either by transcriptional or post-
transcriptional mechanisms.
As a preliminary novelty check, similarity searches were
performed using SciFinder Web (2010-10-21) for data retrieval
from the CAS database (Chemical Abstracts Service, Columbus,
Ohio, USA; www.cas.org). For none of the actives any reference to
COX inhibition was found, and only for compound 9 substructure
Figure 8. COX-2 inhibition in vitro assay results. Shown are COX-1 (blue) and COX-2 (red) inhibition. Celecoxib and SC-560 are known inhibitors
selective for COX-2 and COX-1, respectively.
doi:10.1371/journal.pone.0021554.g008
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to bioactivities other than COX inhibition. It is therefore
reasonable to conclude that COX inhibition by compounds 5
and 9 represents a novel finding resulting from our study. We did
not perform additional analytical investigations of compound
integrity and purity other than those provided by the compound
supplier. Therefore, we cannot exclude that the activities
measured in the assays might be partially owed to decomposition
or oxidation products. Analog compound design and testing will
be mandatory.
Figure 9. COX-2 inhibition whole blood assay results. Shown are TXB2 (blue, indicative of COX-1 activity) and PGE2 (red, indicative of COX-2
activity) amounts relative to the control (DMSO). Celecoxib and SC-560 are known inhibitors selective for COX-2 and COX-1, respectively.
doi:10.1371/journal.pone.0021554.g009
Table 2. Results of in vitro enzyme inhibition assay tests.
COX-1 [%] COX-2 [%]
ID 1 mM 10 mM 100 mM 1 mM 10 mM 100 mM
1’ 66 2.0 96 4.2 156 1.6 196 2.1 236 12:7
{ 176 3.2
2 ? ’ 236 3.5 256 1.0 266 23.5 146 9.7 96 2.2 66 1.6
3 86 1.3 126 3.5 106 5.1 196 0.7 106 1.9 146 0.1
4 66 10.7 266 3.8 226 2.8 36 3.2 36 7.4 216 9.9
5’ 76 3.9 316 3.8 726 4.5 276 8.1 276 1.4 386 3.7
6? 166 4.7 186 9.3 156 1.6 196 68:3
{ 06 10.0 126 2.9
7 26 4.5 46 8.4 76 62:6
{ 206 9.4 136 8.8 156 0.3
8 ? ’ 26 4.5 296 26.8 166 8.0 146 2.6 86 2.1 116 6.2
9’ 66 16.8 466 6.1 896 1.0 96 0.7 246 7.6 386 3.1
10? 276 1.6 2106 8.5 76 2.8 26 5.5 226 2.7 216 3.7
11 116 12.6 56 0.6 16 1.5 56 2.9 46 4.2 06 1.1
12 186 4.0 86 4.5 146 1.5 156 0.1 156 7.5 196 2.2
Primed (0) compounds are shown in Fig. 8, starred (?) compounds are shown in Fig. 9. Discussed compounds are shown in bold face.
{For these three measurements, high standard deviations were observed. This could be due to solubility problems, impurities, protein degradation, or other unspecific
effects. The corresponding measurements should be treated carefully.
doi:10.1371/journal.pone.0021554.t002
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We presented a favorable retrospective evaluation of the SpH
approach using COX-2 data from the DUD collection, and in a
first prospective application demonstrated the usefulness of the
descriptor in combination with a self-organizing map for retrieving
bioactive ligands from a large compound pool. Although we did
not retrieve a potent COX-2 inhibitor, which is likely owed to the
setup of the virtual screening cascade, two novel COX-1 inhibitors
were discovered. Future research will have to focus on mathe-
matical descriptions of molecular shape that allow for enzyme
subtype-selective ligand screening.
We introduced the magnitude of spherical harmonics coeffi-
cients as a partially rotation-invariant descriptor of molecular
shape. In retrospective validation on the DUD dataset, the
performance (as estimated by ROC AUC) of our shape-only
method was comparable to other shape-based similarity searching
methods. Results show that the magnitude of spherical harmonics
decomposition coefficients can be used to describe molecular
shape in a partially rotation-invariant way, resulting in a notable
enrichment of active compounds in virtual and real screening
studies. The combination of pharmacophore filtering by a self-
organizing map and shape-filtering by spherical harmonics
descriptors might be a useful two-step virtual screening protocol
for hit retrieval from large screening compound collections.
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